Company Filing History:
Years Active: 2025
Title: Frederic Vigant: Innovator in Genetic Modification of Lymphocytes
Introduction: Frederic Vigant, based in West Palm Beach, Florida, is a notable inventor renowned for his contributions in the field of genetic modification of lymphocytes. With one patent to his name, Vigant has made significant strides in enhancing methodologies that aim to optimize the modification of immune cells, specifically T cells and NK cells.
Latest Patents: His patent, titled "Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of CD79A and CD79B," introduces innovative approaches to genetically modify lymphocytes more efficiently. This method allows for modifications in shorter times and can be performed using whole blood or its components. Furthermore, his invention employs a lymphodepletion filter assembly, enhancing the process of employing recombinant retroviral particles to achieve successful genetic modifications in a closed system.
Career Highlights: Vigant's career is closely associated with Exuma Biotech Corp., where he has worked tirelessly to advance genetic engineering techniques. His expertise in biotechnology has positioned him as a vital contributor to the company's innovation pipeline, helping to develop treatments aimed at improving immune response.
Collaborations: Frederic Vigant has collaborated with notable coworkers Gregory Ian Frost and James Joseph Onuffer, Jr. These partnerships highlight the dynamic team environment at Exuma Biotech Corp., fostering a culture of innovation and discovery within the realm of biotechnology.
Conclusion: Frederic Vigant’s contributions to the field of genetic modification pave the way for new therapeutic possibilities. His patent underscores a commitment to improving the efficiency of lymphocyte engineering, potentially leading to groundbreaking advancements in medical treatments focused on immune response enhancement. As he continues his work at Exuma Biotech Corp., Vigant remains a pivotal figure in the ongoing evolution of biotechnological innovations.